Fig. 2: Pathologic response and survival data for the population evaluated for neoadjuvant treatment efficacy (N = 45). | Nature Communications

Fig. 2: Pathologic response and survival data for the population evaluated for neoadjuvant treatment efficacy (N = 45).

From: Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial

Fig. 2: Pathologic response and survival data for the population evaluated for neoadjuvant treatment efficacy (N = 45).

A Clinical metadata and analyses for each patient, including smoking and drinking status, clinical response metrics based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, clinical stage, lymph node (LN) metastasis status, and pathological downstaging compared with clinical stage. LN metastasis and pathologic response were determined via a histologic assessment. CR, complete response; PR, partial response; SD, stable disease. B Kaplan–Meier curves for the cumulative survival rates of all patients (n = 45). C Kaplan–Meier curves for cumulative survival rates of pathological complete response (PCR) (n = 14) and non-PCR (n = 31) patients. Log-rank test was used and p = 0.219 (two sided).

Back to article page